Chronic myelomonocytic leukemia (CMML) is a heterogeneous hematopoietic disease currently classified by the WHO organization as an entity close to, but separate from, both myeloproliferative disorders (MPD) and myelodysplastic syndromes (MDS). It is included in the mixed category of MPD/MDS diseases and is defined by persistent peripheral monocytosis (41 Â 10 9 /l), less than 20% blasts in the bone marrow and a variable degree of bone marrow dysplasia. Because of the blast pronostic factor, CMML is divided into two types: type 1 with less than 10% blasts and type 2 between 10 and 19%. [1] [2] [3] The problem of CMML resides in its classification and in the clinical and/or biological relevance of separating the proliferative and dysplastic presentations. The FAB system has recommended a division of CMML into two groups upon leukocyte count: leukocytosis o13 Â 10 9 /l defines CMML as MDS-like (MD-CMML) and leukocytosis 413 Â 10 9 /l as MPD-like (MP-CMML). The two groups have been variably associated with prognosis, and their distinction is a matter of debate. [2] [3] [4] [5] [6] [7] This reflects that, except in a few imatinib-sensitive cases with PDGFRB alterations, the pathogenesis of CMML is poorly understood. Consequently, the definition and therapy of CMML remain unsatisfactory. To both better understand the disease and improve the classification of CMML, we have profiled a series of CMMLs by using DNA microarrays, and compared it with MDS and MPD cases.
After informed consent, we collected 25 samples from 24 patients: 15 CMMLs (8 MD-CMMLs and 7 MP-CMMLs), 2 acute transformations of CMML (AT-CMML), 5 MDSs (1 RARS (refractory anemia with ring sideroblasts), 1 RCMD (refractory cytopenia with multilineage dysplasia), 1 RAEB type 1/refractory anemia with excess of blasts, 1 RAEB type 2 and 1 RAEB type 2 with monocytosis) and 3 MPDs. Classification of the diseases was based on WHO criteria. Patients were newly diagnosed or were known for hematopoietic disease and followed up every 3 months for therapeutic abstention or symptomatic treatment, except for one case. Biological characteristics of the 25 samples are presented in Table 1 and Supplementary Table 1. After bone marrow aspiration, a red cell lysis was performed, followed by rinses with PBS. Leukocytes were processed immediately or cryoconserved at À801C at the sample bank of the Institute and were processed later. DNA and RNA were extracted using NucleoSpin RNA II kit from Macherey-Nagel (Dü ren, Germany) as recommended by the supplier. RNA quality was determined by Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). Mutations at codons 12, 13 and 61 of KRAS and NRAS genes were searched by sequencing the DNA. We found a RAS mutation in two MP-CMMLs (Table 1) .
For RNA expression analysis, we used Affymetrix 133 Plus 2.0 human oligonucleotide microarrays. Preparation of cRNA, hybridizations, washes and detection were carried out as recommended by the supplier and as previously described. 8 Data were analyzed by the Robust Multichip Average method in R using Bioconductor and associated package. Before analysis, a first filtering process removed from the data set the genes with low and poorly measured expression as defined by an expression value inferior to 100 units in all samples. A second filter, based on the intensity of s.d., was applied to exclude genes showing low expression variation across the analyses. For genes with minimal expression value inferior to 100 (our threshold for background) in one sample, s.d. was calculated on values superior to background and a minimal value floored to 100.
A first, unsupervised analysis was performed on the 15 CMMLs. After filtering, 10 051 genes/ESTs (expressed sequence tags) were retained. Before hierarchical clustering, data were log 2-transformed and submitted to the Cluster program using the data median-centered on genes, Pearson correlation as similarity metric and centroid linkage clustering. Results are displayed in Figure 1a using the TreeView program. Two clusters of samples were distinguished. The first cluster (left, S1) comprised seven cases (five MD-and two MP-CMMLs). The second cluster (right, S2) contained eight cases (three MD-and five MP-CMMLs). Thus, global gene expression profiling allowed a clear classification of CMMLs into two major subtypes: S1 contained mainly MD-CMMLs and S2 mainly MP-CMMLs. However, S1 ('dysplastic') and S2 ('proliferative') subtypes did not strictly overlap with the
To identify genes discriminating the two subtypes defined by global expression profiles, a supervised analysis was applied to 20 479 filtered genes/ESTs and to 11 samples constituting the core of the clusters (13, 15, 38, 72, 74, 79 vs 1, 2, 12, 14, 51). Expression data are available in Supplementary Table 2 . We defined a CMML 'proliferative' signature by using a combination of discriminating score (DS) and leave-one-out (LOO) cross-validation. The DS was calculated for each gene and each sample permutation as DS ¼ (M1ÀM2)/(S1 þ S2), where M1 and S1 represent mean and s.d. of expression levels of the gene in subgroup 1 respectively, and M2 and S2 the same in subgroup 2; the confidence levels were estimated by 100 random permutations of samples as described. 9 LOO procedure (11 iterations) allowed the selection of the final discriminator gene list by retaining genes present in all iterations. The procedure was also applied to estimate the accuracy of prediction of the signature and its validity. We identified 1458 differentially expressed probe sets (theoretical number of false positives ¼ 41), of which 1244 were upregulated and 214 downregulated in S2-CMMLs (Supplementary Tables 3 and 4) . These probe sets included 1350 genes (representing 1101 unique genes) and 108 ESTs. To help in the interpretation of the results, we applied the Onto-Express algorithm to the 931 unique genes overexpressed in S2-CMMLs. Supplementary Table 5 shows the most significant (P-value inferior at 3 Â 10
À2
) and most often represented (including at least 10 genes) biological processes. Several of the genes encode signaling proteins involved in the JUN kinase cascade (MAP3 kinases, SYK, PAK1, PAK2, MKNK1, ATF1, STK38) and NFKB pathway (IKIP, IKBKB), suggesting that stress-activated mechanisms are at work in the pathobiology of 'proliferative' CMML (see supplementary figure) . Other upregulated genes suggesting deregulation of apoptosis and inflammation were CARD8, CASP1, CERKL, COP1, NOTCH2, RPS6KA3 and TEGT. Among downregulated genes in S2-CMMLs (upregulated in S1) were IL8 and JUND. To determine the minimal set of discriminator genes, we applied prediction analysis for microarrays (PAM) 10 in R package on the 1458 differentially expressed probe sets identified by LOO. A total of 239 genes/ESTs representing 222 unique genes were identified, which perfectly discriminated S1 from S2 CMMLs by using a threshold of 5.4 (Supplementary  Tables 3 and 4) .
We next tested the classification power of the S1/S2 PAM discriminator list by classifying 25 samples (including 5 MDSs, 3 MPDs and 2 AT-CMMLs, in addition to the 15 CMMLs) according to the correlation coefficient of their expression profile with the median profile of the 'proliferative' CMML. The resulting classification of samples is shown in Figure 1b . The three MPDs (dark blue) clustered with the S2-CMMLs, further suggesting the 'proliferative' feature of the S2 cluster, whereas two MDSs (red) clustered with the S1-CMMLs. The two RAEB2 cases clustered with the MPDs, suggesting that these MDSs may be proliferative.
Thus, our gene expression profiling defines two major CMML subtypes. These subtypes are not associated with leukocyte count, blast proportion or RAS mutation. One possibility is that the two subtypes represent dysplasia vs proliferation, a difference apprehended only poorly by the leukocyte count.
